Mesenchymal stem cells (MSCs) are widely used in regenerative medicine. They can be isolated from different adult tissues. However, the regenerative potential of MSCs obtained from various sources and from different age donors may significantly differ.

The action potential (AP) in cardiac tissue is important for initiating and coordinating contractions in the heart. In addition, the long refractory period minimizes the potential for developing extrasystoles and arrhythmias. The AP is generated by coordinate changes in different ionic currents. In human (or canine) adult ventricular cells, the depolarization phase of the AP is mainly through the influx of Na+ and Ca2+ through specific voltage gated channels.

In many metazoan tissues, highly specialized cells are constantly lost and need to be replaced by tissue homeostasis from adult stem cells. When adult stem cells divide by mitosis their daughter cells either become new stem cells, or enter a proliferation and differentiation path. Recent studies in Drosophila males showed that germline stem cells (GSCs) can increase their mitotic activity in response to repeated mating.

In the previous study, Park et al. reported the efficacy of a single-cell protein manufactured from a growth-accelerated high-vital Corynebacterium glutamicum strain and potential strain selection strategy for development of non-GMO industrial strains harboring enriched target nutritional component, named as growth?acceleration?targeted evolution (G.A.T.E.) strategy [1]. 

Stem cell therapy for the treatment of cerebral palsy is a rapidly expanding area of research that has been identified as a high priority by consumers. There are several types and sources of stem cell therapies under investigation. Stem cell treatments proposed for cerebral palsy are believed to provide benefit via some or all of the following mechanisms including immunomodulation, paracrine signaling and supporting endogenous reparative processes.